Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131323) titled 'A Prospective, Observational, Multicenter, Real-World Study of Toripalimab in the Treatment of Renal Cell Carcinoma' on Sept. 1.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: The Third Medical Centre, Chinese PLA General Hospital, Beijing, China
Condition:
Renal cell carcinoma
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-09-01
Target Sample Size: Renal cell carcinoma observation group:1000;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=331733
Disclaimer: Curated by HT Syndication....